SCHEMBL4053669

SCHEMBL4053669

COc1ccc(CCc2nc3ncc(-c4ccccc4)cc3[nH]2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 5/20 0.71
NOS2 P35228 5/20 0.71
NOS3 P29474 4/20 0.71
AURKA O14965 1/20 0.50
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CYP2C9 P11712 1/20 0.46
IKBKE Q14164 6/20 0.44
TBK1 Q9UHD2 6/20 0.44
FABP4 P15090 1/20 0.44
BRS3 P32247 1/20 0.44
AURKB Q96GD4 2/20 0.42
CDK2 P24941 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
PPARG P37231 1/20 0.41
NTRK1 P04629 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4052894 0.90 NOS1 (0.61) NOS1NOS2NOS3AURKALMNA
SCHEMBL4052457 0.89 NOS3 (0.63) NOS1NOS2NOS3AURKALMNA
SCHEMBL4054567 0.89 NOS1 (0.72) NOS1NOS2NOS3AURKALMNA
SCHEMBL4061688 0.88 NOS1 (0.59) NOS1NOS2NOS3AURKALMNA
SCHEMBL4054242 0.88 NOS3 (0.59) NOS1NOS2NOS3AURKALMNA
SCHEMBL4058698 0.88 NOS3 (0.62) NOS1NOS2NOS3LMNAHTT
SCHEMBL4055334 0.87 NOS3 (0.59) NOS1NOS2NOS3LMNAHTT
SCHEMBL4053930 0.84 NOS3 (0.56) NOS1NOS2NOS3LMNAHTT
SCHEMBL4057994 0.84 NOS3 (0.56) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4057459 0.84 NOS3 (0.56) NOS1NOS2NOS3SMN1; SMN2BRS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS1 879/4885NOS2 1019/4885NOS3 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.